Principal Consultant, Trial Equity
Otis Johnson, PhD, MPA
Dr. Otis Johnson stands out as a leading authority in clinical research and championing diversity within the pharmaceutical industry. His career began with a transformative 13-year tenure at Merck & Co., where he played a critical role in the approval of Singulair for exercise-induced bronchospasm and helped establish the Global Trial Optimization group. His expertise flourished at Syneos Health and ICON, where he spearheaded advancements in clinical development strategies, focusing on feasibility, clinical informatics, and patient recruitment.
As a product management executive at Clario, Otis significantly contributed to the growth of the Trial Oversight analytics product line, turning it into a $30 million venture. He also elevated the organization’s ESG ratings in his role as the Chief Diversity, Inclusion, and Sustainability Officer.
Recognized as a PharmaVoice 100 Most Inspiring Industry Leader, a top DE&I Leader by Mogul, and honored with the Healthcare Businesswomen’s Association (HBA) Honorable Mentor Award, Otis’s influence extends far beyond his immediate professional circle. In his current role as Co-founder and Principal Consultant of Trial Equity, Otis works to equip clinical research professionals with the knowledge and skills to enroll more representative patient populations into clinical trials to ensure that medicines are safe and effective for all people.
Contact: +1908-487-1624, Otis.johnson@trialequity.com